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A novel splice variant of hPirh2, named hPirh2b, was isolated from human fetal liver cDNA library.
hPirh2b has a 38-nucleotide deletion and encodes a 188-amino acid protein with a truncated RING-
H2 domain. It shows no ubiquitin protein ligase activity. A low level of expression of hPirh2 was
found both at transcriptional and translational level in human hepatocellular carcinoma (HCC)
when compared to non-cancerous tissue. Statistical analysis showed that the low expression is asso-
ciated with lack of differentiation of HCC. In direct binding studies hPirh2b bound p53 indicating
that RING-H2 domain is not needed for this interaction.
Structured summary:
MINT-7889990: NTKLBP1 (uniprotkb: Q5T7V8) physically interacts (MI:0915) with Pirh2b (uni-
protkb:Q2KN33) by two-hybrid (MI:0018)
MINT-7890105: hPirh2b (uniprotkb:Q2KN33) physically interacts (MI:0915) with p53 (uniprotkb:P04637)
by anti tag coimmunoprecipitation (MI:0007)
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Ubiquitin-mediated protein degradation plays an important
role in controlling the levels of various cellular proteins and there-
fore impacts on diverse cellular processes such as cell cycle pro-
gression, receptor modulation, transcription regulation and signal
transduction. The key components that dictate its substrate speci-
ﬁcities are E3 ubiquitin ligases. Most E3 ligases are differentially
expressed in cancers. Targeting E3 ubiquitin ligases for cancer
therapy has gained increasing attention, largely because of their
ability to trigger the degradation of oncogenes or tumour suppres-
sors [1–4]. So E3 ligases represent potential therapeutic targets.
Pirh2 is a newly identiﬁed RING ﬁnger protein with E3 ligase
activity. Its notable feature is a capacity to negatively regulate
p53 through physical interaction and ubiquitin-mediated proteol-
ysis independent of Mdm2 [5]. It was initially cloned as androgen
receptor N-terminal interacting protein [6]. In northern blot anal-
ysis in various adult mouse tissues, it occurs as two transcripts ofchemical Societies. Published by E
G-H2 protein; HCC, human
N-terminal interacting pro-1.7 and 1.6 kb [5]. Human p53-induced RING-H2 protein (hPirh2)
consists of 261 amino acids and has a RING-H2 (C3H2C3) ﬁnger do-
main. It is deﬁned by a consensus sequence with six cysteines and
two histidines that coordinate two zinc ions accounts for E3 ligase
activity of Pirh2 in vitro and in vivo [6].
Here, we describe the identiﬁcation and characterization of a
novel splicing variant of hPirh2 from human fetal liver cDNA li-
brary. We named this novel splicing variant as hPirh2b. The expres-
sion pattern of hPirh2 in various human normal tissues, human
hepatocellular carcinoma (HCC) and non-cancerous tissues was
studied. We also show that hPirh2b, which lacks RING-H2 domain,
has no ubiquitin ligase activity. It can interact with p53 in vitro and
in vivo. These results will help us to understand the potential role
of Pirh2 in the development of HCC.2. Materials and methods
2.1. Yeast two-hybrid screening
The coding sequence of hNTKLBP1 (human N-terminal kinase-
like-binding protein 1, NM_152281.2) was cloned into pGBKT7 as
a bait and the recombined plasmid was transfected into the yeast
strain AH109 followed by the protocol of pACT2 human fetal liver
cDNA library (CLONTECH MATCHMAKER Two-Hybrid system 3).lsevier B.V. All rights reserved.
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instruction. Prey plasmids were isolated and sequenced, followed
by homology search using the BLAST algorithm on NCBI web site
(http://www.ncbi.nlm.nih.gov).
2.2. Northern blot analysis
Northern blot analysis was carried out using Human 8-lane
MTN Blot membrane (CLONTECH). The hPirh2 cDNA probe was la-
beled with [a-32P]dCTP using Random Primer DNA Labeling Kit
(Takara). Prehybridization was done at 68 C for 3 h with herring
sperm DNA. Hybridization was at 68 C overnight followed by
washing and autoradiography at 70 C.
2.3. Quantitative real-time reverse transcription PCR
Pieces of HCC tissues were collected from tumors of patients
undergoing surgery at Zhong Shan Hospital, Shanghai. Total RNA
from normal and tumor tissues was extracted by TRIzol (GibcoBRL)
and then treated with ampliﬁcation grade DNase I (Invitrogen) be-
fore cDNA synthesis. Reverse transcription was carried out with
Reverse Transcriptase Kit (Takara). qPCR was performed in tripli-
cate using Sybr Green Mastermix on the ABI Prism 7900 Sequence
Detection System (Applied Biosystems). GAPDH was used as an
endogenous control. qPCR conditions were 95 C for 15 min, 40 cy-
cles of 95 C for 15 s and 60 C for 1 min, followed by the condition
for melt curve analysis to conﬁrm the speciﬁcity of the ampliﬁca-
tion product: 95 C for 15 s, 60 C for 15 s and 95 C for 15 s. PCR
primer sequences are as follows: hPirh2, 50-TATGACCAGGTATTGG
AGACAGC-30(sense), 50-CAGTGAAATTCTACGTCCTCCAG-30(anti-
sense); hPirh2b, 50-GAAATGTTGAAAGAATATGACCAGG-30(sense),
50-GAACAGTGGATCGTCCATTACAGT-30(antisense); GAPDH, 50-
GCACCGTCAAGGCTGAGAAC-30(sense), 50-ATGGTGGTGAAGACGCC
AGT-30(antisense).
The primers of hPirh2b were designed to anneal the splice junc-
tion of exon7 and exon8 of hPirh2 uniquely, ensuring speciﬁc
ampliﬁcation of hPirh2b.
2.4. Tissue microarray-based immunohistochemistry
The expression of hPirh2 protein in HCC was analyzed using tis-
sue microarray (TMA), which contained 190 pairs of HCC tissue
and surrounding liver tissue. Six normal liver tissue samples from
hepatic haemangioma were selected as normal controls. All liver
tissues were veriﬁed by pathological examination. Immunohisto-
chemistry analysis was performed using the Elivision plus two-
step System (Dako, Carpinteria, CA) following manufacturer’s
instructions. Slides were incubated with primary 1:25 anti-hPirh2
rabbit pAb antibody (Merck). Diaminobenzidine and hematoxylin
were used as chromogen and counterstain, respectively. Dark
brown granules were taken as positive reaction.
2.5. Glutathione S-transferase (GST) pull-down assay
hPirh2 and hPirh2b were cloned into pGEX4T-1 vector (Amer-
sham Pharmacia Biotech) to generate constructs encoding GST-
hPirh2 and GST-hPirh2b fusion proteins. p53 (72–390aa) was
cloned into pGBKT7 which contains a c-Myc epitope tag. Myc-
p53 fusion protein was produced by the TNT-coupled reticulo-
cyte lysate system (Amersham Pharmacia Biotech) following
the manufacturer’s instruction and detected by Western blot
with anti-Myc antibody (Invitrogen). For interaction studies,
GST-hPirh2 and GST-hPirh2b were allowed bind to glutathi-
one-Sepharose 4B beads which were then incubated with 5 ll
Myc-p53 protein in 200 ll NETN buffer (50 mM Tris–HCl, pH
7.5, 200 mM NaCl, 2 mM EDTA, 0.1% NP-40, 1 mM PMSF) for3 h at 4 C, respectively. The beads were washed three times
by H buffer (20 mM HEPES, 50 mM KCl, 20% glycerol, 0.1% Non-
idet P-40, and 0.007% b-mercaptoethanol). Then the pellets
were boiled in 20 ll loading buffer, subjected to 15% SDS–PAGE,
transferred to PVDF membrane and immunoblotted with anti-
Myc antibody.
2.6. Co-immunoprecipitation assay in vivo
hPirh2b was cloned into pCMV-Myc (Clontech) to produce Myc
tagged hPirh2b. Wild-type p53 expression vector (pcDNA3.0-p53)
was generously provided by Dr. Long Yu. 2.6  106 HEK293T cells
were maintained in DMEM supplemented with 10% bovine calf
serum (GIBCO), grown on 60 mm dishes before the day of trans-
fection. 5 lg total DNA of either Myc-hPirh2b and pcDNA3.0-p53
or pCMV-Myc and pcDNA3.0-p53 (in 1:1 molar ratio) was trans-
fected with Lipofectamine 2000 reagent (Invitrogen) following
the operation protocol. 48 h later, cells were washed twice with
ice-cold PBS and lysed with 1 ml lysis buffer (20 mM Tris, pH
7.5, 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 10% glycerol,
2.5 mM Na4P2O7, 1% Triton, 1 mM Na3VO4, 1 mM b-glycerophos-
phate, 10 lg/ml aprotinin, 10 lg/ml leupeptin, and 1 mM PMSF).
Lysate supernatant was incubated with EZview™ Red Anti-c-Myc
Afﬁnity Gel (Sigma) and co-immunoprecipiation was done accord-
ing to the operation manual. Samples were resolved by 12% SDS–
PAGE and subjected to Western blotting using anti-p53 antibody
(Calbiochem).
2.7. Ubiquitination assay in vitro
The ubiquitination assay was performed according to a previ-
ously published report [7] with modiﬁcations. GST-hPirh2 or
GST-hPirh2b immobilized to the glutathione-Sepharose 4B beads
was combined with rabbit E1 (40 ng, Calbiochem), UbcH5b
(100 ng, Calbiochem), His-tagged ubiquitin (2 lg, Calbiochem) in
a ubiquitination buffer (50 mM Tris–HCl (pH 7.4), 2 mM ATP,
5 mM MgCl2, 2 mM DTT, 30 mM creatine phosphate, 0.05 mg/ml
creatine phosphokinase and BL-21 cell lysates), and the mixture
was incubated at 30 C for 1.5–2 h. The reaction was terminated
by adding loading buffer and processed for 12% SDS–PAGE. Wes-
tern blot experiments were done using the anti-His antibody
(Invitrogen).
2.8. Subcellular localization
Hela cells were cultured in DMEM, supplemented with 10% fe-
tal bovine serum (Life Technologies) under the condition of 5%
CO2 at 37 C. hPirh2 and hPirh2b were cloned into the pEGFP-C1
plasmid (Clontech) to generate the expression constructs pEG-
FP-C1-hPirh2 and pEGFP-C1-hPirh2b in which GFP is tagged to
the N-terminus of hPirh2 and hPirh2b. All transfections were per-
formed using Lipofectamine 2000 reagent. After 48 hrs, ﬂuores-
cent image analysis was performed using confocal laser
scanning microscopy (Zeiss LSM 510 META, Axiovert 200,
Germany).
2.9. Statistical analysis
t-test was used to analyze the relationship between the
expression of hPirh2 as determined by qPCR and the differentia-
tion of HCC. For the result of TMA, chi-square test was applied
to assess the differences of hPirh2 protein expression between
HCC and the surrounding liver tissue. A probability level of
0.05 was chosen for statistical signiﬁcance. Statistical analysis
was performed with the SPSS12.0 software package (Chicago, IL,
USA).
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3.1. Isolation of hPirh2b from fetal liver cDNA library and sequence
characterization of hpirh2b
Apart from hPirh2 identiﬁed as the interaction protein of
hNTKLBP1 by yeast two-hybrid in [8], a cDNA of 1320 nt was se-
lected for closer scrutiny. Sequencing revealed an open reading
frame of 564 nucleotides corresponding to the nt 27–590 in the
original contig (GenBank accession number AY888047) (Fig. 1).
From the nucleotide sequence of 564 nt ORF, a protein sequence
of 188 amino was deduced, with a calculated molecular mass of
20.7 kDa. Comparison with hPirh2 shows 96% identity. SMART
analysis (http://smart.embl-heidelberg.de/) revealed a Znf_CHY
domain. Furthermore, when compared with hPirh2, a deletion of
38 nucleotides was found in hPirh2b, corresponding to the RING
ﬁnger domain in Pirh2.Fig. 1. The nucleotide and deduced amino acid sequences of hPirh2b. Start and stop codo
box. Two dark shadings highlight a conﬁdently predicted Znf_CHY domain (aa20–94) anSearch against the genome database revealed that hPirh2b was
represented by a genomic contig (NT_086651) in chromosome
4q21. The coding region of hPirh2b can be divided into eight exons
through alignment of the hPirh2b cDNA with this genomic contig
(Fig. 2). All the putative exon–intron junctions conform to the
GT/AG rule (Table 1). Compared with another splicing variant of
hPirh2 (accession number NM_015436), hPirh2b uses a different
50 splice site in exon 8. This results in a 38-nucleotide deletion in
50 terminus of exon8 and creates a premature termination codon
in exon 8. Thus, the exons 6 and 7 and parts of exons 5 and 8,
encoding RING-H2 domain in Pirh2 are spliced out in hPirh2b.
3.2. Expression of hPirh2 in normal and HCC/non-cancerous tissue
The expression of hPirh2 in normal tissue investigated by North-
ern blot (Fig. 3A). Highest level of expression was found in heart
and skeletal muscles, followed by liver and pancreas. The expres-ns are marked in bold italics type. The polyadenylation signal is indicated by black
d a truncated RING ﬁnger domain (aa145–178).
Fig. 2. The schematic representation of two splicing variants of hPirh2 and comparison of the RING-H2 domains. (A) hPirh2 and hPirh2b have 9 and 8 coding exons,
respectively. (B) The conserved cysteine and histidine residues in RING-H2 domain (C3H2C3) are indicated by black box. In the truncated RING-H2 domain of hPirh2b, the
seventh and eighth cysteines are lost.
Table 1
Exon–intron boundary sequence of hPirh2b.
Exon cDNA position Splicing acceptor Splicing donor Intron
Number Length (bp) Position at NT_086651 Gene Number Length (bp)
1 90 23511578–23511667 27-116 – TCTCCTAAAGgtgacgcctt –
2 120 23506538–23506657 117-236 tgggtgttagGCACCTTGCT AATTCAACATgtaagatttt 1 4920
3 116 23506181–23506296 237-352 tcttttttagGCCCAACAGA GAATTTGTAGgtactgtagg 2 241
4 79 23491719–23491797 353-431 gttttgctagGATTGGTCCA AAGACACAAGgtatataatt 3 14383
5 45 23489507–23489551 432-476 ttttaaacagTGTATTGAAA ATGTTTGGAGgtaggcttaa 4 2167
6 59 23489342–23489400 477-535 tcatttacagGACATTCACA TTTTACATAGgtaaagtaac 5 106
7 27 23489229–23489255 536-562 tttctttcagAACGTGTTAT TGTTGAAAGAgtgagtgttt 6 86
8 28 23488254–23488281 563-590 tctgctttagATATGACCAG – 7 947
Intron and exon nucleotide sequence are shown in lowercase and uppercase letters, respectively. Bold italics lettering indicates donor and acceptor splice site.
Not including 50 or 30 UTRs or stop codon.
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only at a low level.
By qPCR analysis of 79 pairs of HCC/non-cancerous tissues, we
found that the level of expression of hPirh2 was lower in 66% cases
(52) when compared with the corresponding normal liver. hPirh2b
was found at lower level of expression in 58% of cases when com-
pared with the normal tissue (Fig. 3B). Statistically, a signiﬁcant
correlation could be seen between a low level of expression of
hPirh2 (when compared with normal tissue) and the lack of differ-
entiation of HCC (P < 0.05 t-test). However, there was no associa-
tion between the differential expression of hPirh2b and the
differentiation grade of HCC.
Also TMA-based immunohistochemistry revealed a low level of
expression of hPirh2 in HCC when compared with normal tissue;
39% positive (74 out of 190) in HCCs; 73% positive1 (39 out of
190 tissues) in normal tissue; P = 1.839E-11) (Fig. 3C and D).
3.3. hPirh2b can interact with p53 in vitro and in vivo
GST pull-down assay was applied to tell whether or not hPirh2b
can interact with p53. GST-hPirh2 and GST-hPirh2b fusion proteins
were expressed in E. coli strain BL-21. The calculated molecular
weights of the expressed fusion proteins are 58 and 49 kDa, corre-spondingly, as determined by 12% SDS–PAGE (Fig. 4A). Immuno-
blotting with ant-Myc antibodies showed that the myc-p53
fusion protein was bound to GST-hPirh2 and GST-hPirh2b fusion
proteins but not GST alone (Fig. 4B).
To further conﬁrm the interaction between hPirh2b and p53,
co-immunoprecipitation experiment was carried out. We found
that p53 was present in the Myc-hPirh2b immunoprecipitates
but not in the pCMV-Myc immunoprecipitates (Fig. 4C).
3.4. hPirh2b has no ubiquitin protein ligase activity
An in vitro ubiquitination assay system was used to determine
whether hPirh2b can mediate protein ubiquitination. Afﬁnity puri-
ﬁed GST-hPirh2, GST-hPirh2b and GST were added to bacterial
extracts containing E1, E2 (UbcH5b) and His-tagged ubiquitin,
respectively. After the ubiquitination reaction, the samples were
subjected to SDS–PAGE and immunoblotted with His antibody to
detect ubiquitinated products. Positive immunoreaction was seen
only in lane 1 indicating that GST-hPirh2 fusion protein but not
GST-hPirh2b nor GST can catalyze the autoubiquitination activity
(Fig. 5). Thus, it can be concluded that hPirh2b is devoid of
ligase activity. This is most likely due to its lack of the RING-H2
domain.
Fig. 3. (A) Expression patterns of hPirh2 in various human normal tissues. Three hPirh2 transcripts of about 1.6, 1.7 and 4.4 kb were detected. (B) qPCR results of hPirh2 and
hPirh2bwere normalized and converted into ratio against the expression level of GAPDH. (C and D) Normal liver tissue and HCC was immunostained with anti-Pirh2 antibody
respectively. Positive staining is indicated as brown color.
Fig. 4. Interaction of hPirh2 and hPirh2b with p53 in vitro and in vivo. (A) GST-hPirh2, GST-hPirh2b and GST were expressed and puriﬁed respectively. (B) p53 binds to hPirh2
and hPirh2b, but not to GST alone. The translation product of p53 in vitro was used as a control. (C) hPirh2b interacts with p53 in vivo. Myc-hPirh2b and p53 were co-
transfected into HEK293T cells. Myc tagged vector and p53 were co-transfected as control. Lysate was immunoprecipitated with anti-Myc antibody and analyzed by
immunoblotting with anti-p53 antibody.
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In an attempt to identify whether the truncated RING-H2
domain will inﬂuence the subcellular localization of hPirh2,
we produced expression constructs in which GFP is tagged to
the N-terminus of hPirh2 and hPirh2b. GFP-hPirh2 exhibited adiffuse nuclear and cytoplasmic distribution which is in agree-
ment with previous reports (data not shown) [9–11]. However,
there is no signiﬁcant difference about the subcellular localiza-
tion of hPirh2b from hPirh2. hPirh2b homogeneously distrib-
uted throughout the cytoplasm and the nuclei in Hela cells
(Fig. 6).
Fig. 5. hPirh2b has no ubiquitin protein ligase activity. GST-hPirh2, GST-hPirh2b
and GST were evaluated for E3 activity in the presence of E1, E2, and His-tagged Ub
as indicated. No ubiquitinated products were detected in the presence of GST or
GST-hPirh2b.
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Here we report cloning and characterization of a novel splice
variant of hPirh2. Recently, three other isoforms of hPirh2 were
identiﬁed in [11,12]. Common to these variant forms is that they
show alternative splicing in the RING-H2 domain [11]. Alternative
pre-mRNA splicing is a sophisticated and ubiquitous nuclear pro-
cess which plays an essential role in the regulation of many bio-
logic processes. Increasing amounts of evidence strongly suggest
that the alternative pre-mRNA splicing of some E3 ligases occurs
frequently in human cancer cells [13,14].
Pirh2 was originally identiﬁed as a p53-inducible and p53-
interacting protein which promotes p53 ubiquitination and degra-
dation [5]. It had been found to be expressed higher in lung cancer,
prostatic carcinoma, head and neck cancer [10,15,16]. During the
preparation of this manuscript, Wang et al. found that the in-
creased expression levels of Pirh2 were correlated with a poor
prognosis in HCC patients [17]. That suggested Pirh2 could be as
a potential drug target and a prognostic biomarker of cancers.
However, further studies are still needed to explore the potential
role which hPirh2b plays in the genesis and progression of HCC.Fig. 6. Subcellular localization of GFP-tagged hPirh2b. hPirh2b homogeneously distribu
DAPI.Given Pirh2 has been shown to be one of the interaction protein
of p53 [5], we next sought to investigate the relationship between
hPirh2b and p53. Although there is a RING domain deletion in
hPirh2b, the interaction between hPirh2b and p53 have been found
by GST pull-down assay and co-immunoprecipitation, which sug-
gested that the intact RING-H2 domain is not necessary for
Pirh2–p53 interaction. RING-H2 is commonly found in ubiquitin li-
gases. Thus, it was pertinent to test whether Pirh2b, analogous to
Pirh2, has ubiquitin ligase activity. Ubiquitin assay failed to show
any ligase activity pointing out to the central role of RING-H2 in
this activity. Interestingly, a RING-less mutant of mPirh2 and an-
other two hPirh2 RING-H2 domain variants retain the ability to re-
press p53-mediated transcriptional activity [5,11], a functional
feature of intact Pirh2. Thus, Pirh2 is able to affect the transactiva-
tion function of p53 by using some other mechanism than ubiqui-
tination followed by degradation. The present results suggest that
hPirh2b utilizes similar, ubiquitin-independent mechanisms in its
functional interaction with p53. Its differential expression in vari-
ous tissues and tumors may be a reﬂection of its differential role in
p53-mediated tumorigenesis.
In some studies, presence or absence of RING domain has been
found to be associated with altered subcellular distribution of
some ubiquitin protein ligases with putative pathogenetic signiﬁ-
cance [18]. The nuclear and nucleolar subcellular localization play
an essential role in the function and stability of Pirh2 [9]. No signif-
icant difference was found in the subcellular localizations of
hPirh2b from hPirh2. Thus, presence or absence of RING-H2 does
not seem to be associated with the altered subcellular distribution
at least at the light microscopic level. In previous reports, mPirh2
transcripts of 1.6 and 1.7 kb were found in various adult mouse tis-
sues [5,6]. In addition, a minor 1.3 kb transcript was only detected
in rat PC-12 (rat adrenal pheochromocytoma) cells and mouse TM-
4 (mouse Sertoli cells) cells [6]. These results suggest that Pirh2
isoforms are expressed differentially among tissues. To date, more
than 40 different splicing variants of Mdm2 transcripts have been
identiﬁed both in tumors and normal tissues. Most of them are
associated with tumor progression and prognosis [19–21]. Due to
the similar type of functional partnership of Mdm2 and Pirh2 in
relation to p53, it can be surmised that the tissue variable Pirh2
isoforms could provide tissue speciﬁc regulatory pathways under-
lying some speciﬁc tumorigenic pathways.
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